drugset / Trial / NCT06184698
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, single-arm study to investigate the efficacy and safety of liposomal irinotecan+5-FU/LV+ bevacizumab as second-line therapy in metastatic colorectal cancer in Chinese population.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2026-02-01
- Completion
- 2027-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |
| Subject | IRINOTECAN | Small molecule | 70 mg/m2 | — |
| Subject | LV | Unknown | — | — |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | — |